Addyi vs Vyleesi Side-Effect Profile: A Head-to-Head Comparison

What Are Addyi and Vyleesi?

Both drugs treat hypoactive sexual desire disorder (HSDD), a diagnosable condition characterized by persistent low sexual desire that causes personal distress. The two medications reach that target through completely different mechanisms, which directly explains why their side-effect lists look so different.

Flibanserin (Addyi): A Central Serotonin Modulator

Flibanserin acts on serotonin 1A receptors as a partial agonist and on serotonin 2A receptors as an antagonist, while also exhibiting weak dopamine D4 agonist activity. The FDA approved it in August 2015 after two earlier rejections, largely on the strength of phase III data showing statistically significant but modest improvements in satisfying sexual events (SSEs) and sexual desire scores. The drug label carries a Risk Evaluation and Mitigation Strategy (REMS) because of the alcohol-interaction risk. Full FDA prescribing information is available from the FDA label database.

Bremelanotide (Vyleesi): A Melanocortin Receptor Agonist

Bremelanotide is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It activates melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system to modulate sexual motivation pathways. The FDA approved it in June 2019. It is injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours. The FDA's full prescribing information for Vyleesi outlines its cardiovascular precautions in detail. FDA Vyleesi label

The Key Trials: BEGONIA and RECONNECT

Understanding side-effect rates requires going back to the trial populations and endpoints, because no published head-to-head trial has directly compared Addyi and Vyleesi in the same cohort.

BEGONIA Trial (Flibanserin, J Sex Med 2014)

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014, randomized premenopausal women with HSDD to flibanserin 100 mg nightly or placebo. BEGONIA primary publication on PubMed The trial demonstrated a statistically significant improvement in SSEs and desire scores versus placebo. Somnolence occurred in approximately 11.4% of flibanserin patients versus 3.8% on placebo. Dizziness was reported by 10.9% versus 2.0%, and nausea by 9.2% versus 4.0%. These CNS-mediated effects directly reflect flibanserin's serotonergic mechanism. The trial did not include an alcohol-challenge arm; the hypotension signal emerged in separate dedicated interaction studies conducted before the second FDA advisory committee.

RECONNECT Trials (Bremelanotide, Obstet Gynecol 2019)

The RECONNECT program consisted of two identically designed phase III, randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD, published in Obstetrics and Gynecology in 2019. RECONNECT publication on PubMed Across both trials (combined N=1,267), bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire domain and in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score versus placebo. Nausea was the leading adverse event, occurring in approximately 40% of bremelanotide-treated women versus 1.3% on placebo. Flushing affected roughly 20% and headache approximately 11%. A transient mean increase in systolic blood pressure of about 4 to 6 mmHg was documented post-injection, typically resolving within 12 hours. PubMed: bremelanotide cardiovascular pharmacology

Side-Effect Profiles: A Systematic Comparison

This is where the two drugs diverge most clinically. The table below organizes trial-reported adverse events by system.

| Adverse Event | Addyi (flibanserin) | Vyleesi (bremelanotide) | |---|---|---| | Nausea | ~9% | ~40% | | Dizziness | ~11% | ~2% | | Somnolence | ~11% | <2% | | Flushing | <3% | ~20% | | Headache | ~8% | ~11% | | Hypotension (alone) | ~0.6% | Not reported | | Hypotension (with alcohol) | Severe; boxed warning | Not a primary concern | | Blood-pressure increase | Not reported | ~4 to 6 mmHg transient rise | | Injection-site reactions | N/A | ~13% (bruising, pain) | | Hyperpigmentation | Not reported | ~1% (face, breast, gums) |

CNS Side Effects: Addyi's Primary Liability

Flibanserin's serotonin and dopamine activity means CNS depression is its signature problem. The FDA label notes that somnolence, sedation, and fatigue affect a meaningful percentage of users, which is why the drug must be taken at bedtime rather than in the morning. FDA flibanserin label

The alcohol interaction is not theoretical. In a dedicated pharmacokinetic/pharmacodynamic interaction study, a single 0.4 g/kg dose of alcohol (roughly two standard drinks) combined with flibanserin 100 mg produced clinically significant hypotension and syncope in 4 of 23 subjects, compared with none on alcohol alone. NIH alcohol-flibanserin interaction data via NIAAA That finding drove the REMS requirement and the boxed warning, which states that patients must commit to complete alcohol avoidance during treatment. Strong and moderate CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice at more than one cup daily) also raise flibanserin plasma levels significantly and carry the same severe hypotension risk. PubMed: flibanserin drug interactions

Cardiovascular Side Effects: Vyleesi's Primary Liability

Bremelanotide's melanocortin receptor activity temporarily raises blood pressure through a centrally mediated mechanism. The RECONNECT trials recorded a mean transient systolic increase of 4 to 6 mmHg and diastolic increase of approximately 3 mmHg after each injection, with most values returning to baseline within 12 hours. RECONNECT on PubMed The FDA label therefore contraindicates bremelanotide in women with known cardiovascular disease or uncontrolled hypertension. Because of this transient pressor effect, patients should not use Vyleesi more than once every 24 hours, and the label advises against use in women for whom blood-pressure elevations would pose serious risk.

Nausea: Vyleesi's Most Common Complaint

Approximately 40% of women in RECONNECT reported nausea, and about 13% rated it severe enough to affect their activities. RECONNECT on PubMed Prescribers commonly recommend pre-treating with a non-prescription antiemetic such as ondansetron or promethazine 30 minutes before injection to blunt this effect, though this is an off-label practice. Nausea generally resolved within one to two hours post-injection.

Addyi's nausea rate of approximately 9% in BEGONIA was lower and consistent with its twice-daily dosing regimen in early trials before the final 100 mg nightly dose was settled. BEGONIA on PubMed

Hyperpigmentation: A Unique Vyleesi Concern

A small but clinically notable proportion of bremelanotide users (roughly 1%) developed focal hyperpigmentation of the face, breasts, or gums with prolonged use. This results directly from MC1R activation driving melanin production. The FDA label recommends discontinuation if hyperpigmentation develops and notes that it may not fully resolve. FDA Vyleesi label Addyi carries no pigmentation risk.

Contraindications and Drug Interactions

The two drugs differ as sharply in their contraindications as in their side effects.

Addyi Contraindications

Flibanserin is contraindicated with:

• Any alcohol consumption (boxed warning)
• Moderate or strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors, grapefruit juice)
• Hepatic impairment of any degree
• Use with other CNS depressants (opioids, benzodiazepines, sleep aids)

The REMS program requires both the prescriber and the dispensing pharmacy to be certified, and patients sign an acknowledgment that they have been counseled on the alcohol prohibition. FDA REMS database

Vyleesi Contraindications

Bremelanotide is contraindicated with:

• Known cardiovascular disease (history of MI, stroke, uncontrolled arrhythmia)
• Uncontrolled hypertension (systolic blood pressure above 165 mmHg or diastolic above 100 mmHg)
• Known hypersensitivity to bremelanotide or any excipient

It does not interact meaningfully with alcohol and carries no CYP enzyme-based drug interactions of clinical significance, making it more straightforward in polypharmacy situations. FDA Vyleesi label

Efficacy Signals: How Much Do They Actually Help?

Side effects only matter alongside efficacy. Both drugs showed statistically significant results in their key trials, but the absolute effect sizes are modest.

Flibanserin Efficacy Numbers

Across the phase III trials submitted to the FDA, flibanserin produced an increase of approximately 0.5 additional satisfying sexual events per month versus placebo after 24 weeks of treatment. Desire scores on the Female Sexual Function Index improved by a mean of about 0.3 to 0.4 points more than placebo. FDA advisory committee briefing document for flibanserin The FDA's own medical review noted that the clinical significance of this magnitude of improvement remains a subject of ongoing discussion among specialists in sexual medicine.

Bremelanotide Efficacy Numbers

In RECONNECT (N=1,267), bremelanotide-treated women showed a mean improvement in the FSDS-DAO score of 3.6 points versus 1.5 points for placebo, a statistically significant difference (P<0.001). The desire domain of the Female Sexual Function Index improved by approximately 0.3 to 0.4 points more than placebo. RECONNECT on PubMed Roughly 25% of bremelanotide users were classified as responders by a predefined threshold, versus about 17% on placebo.

The American College of Obstetricians and Gynecologists (ACOG) notes in its guidance on female sexual dysfunction that "pharmacologic options for HSDD should be discussed in the context of modest average effect sizes and individual variability in response." ACOG practice resources

Who Is a Better Candidate for Each Drug?

Selecting between the two drugs depends less on efficacy (which is comparable) and more on the patient's lifestyle, comorbidities, and tolerance for specific adverse effects. The following framework organizes key decision points.

Consider Addyi When:

• The patient does not drink alcohol and can commit to complete abstinence
• She prefers a daily oral pill rather than an injectable
• She does not take CYP3A4 inhibitors and has no hepatic impairment
• Her blood pressure is normal or low-normal and cardiovascular risk is low
• She finds the predictability of a nightly medication preferable to an as-needed approach

Consider Vyleesi When:

• The patient drinks alcohol socially and is unwilling or unable to abstain
• She prefers on-demand dosing only before anticipated activity rather than daily medication
• She has no cardiovascular disease or uncontrolled hypertension
• She can tolerate a subcutaneous self-injection
• She is comfortable managing nausea with a pre-dose antiemetic

A 2021 review in the Journal of Sexual Medicine examining real-world prescribing patterns found that patients who chose bremelanotide over flibanserin most commonly cited alcohol use and discomfort with strict dietary restrictions as the deciding factor. PubMed: real-world HSDD prescribing patterns

Dosing and Administration

Addyi Dosing

• 100 mg oral tablet taken once nightly at bedtime
• Do not take during waking hours (worsens CNS depression and fall risk)
• Re-evaluate after 8 weeks; discontinue if no meaningful benefit by week 8
• Available only through certified pharmacies under the REMS program

Vyleesi Dosing

• 1.75 mg subcutaneous injection administered 45 minutes before anticipated sexual activity
• Maximum one dose per 24-hour period
• Inject into the abdomen or thigh; rotate injection sites
• No ongoing daily commitment required

What Happens If You Stop Either Drug?

Neither drug produces physical dependence or a withdrawal syndrome. Discontinuing flibanserin simply removes its serotonergic effects; there is no rebound worsening documented in the phase III trial data beyond return to baseline desire scores. BEGONIA on PubMed Stopping bremelanotide likewise results in return to pre-treatment function with no rebound effect documented in RECONNECT. RECONNECT on PubMed

The North American Menopause Society (NAMS) guidelines state that "either agent may be discontinued without tapering; treatment duration should be guided by ongoing patient-reported benefit and tolerability." NAMS position statement on sexual health

Monitoring Requirements During Treatment

Monitoring for Addyi Users

• Blood-pressure check at baseline and again at 4 weeks if hypertension history exists
• Liver function tests at baseline given the hepatic contraindication
• Reassess for alcohol use at every visit; the REMS requires documented counseling
• Screen for concurrent CNS depressant use (opioids, benzodiazepines, antihistamines)

Monitoring for Vyleesi Users

• Blood pressure at baseline; recheck if symptoms of palpitations or headache occur post-injection
• Skin examination for new hyperpigmentation at 3 and 6 months
• No routine labs required beyond baseline cardiovascular risk assessment
• Assess nausea severity at first follow-up; consider pre-dose antiemetic if severe

A 2020 pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data identified syncope and hypotension as the most frequently reported serious events for flibanserin, while nausea and vomiting dominated the bremelanotide serious-event reports. PubMed: FAERS flibanserin safety analysis

Cost, Access, and Insurance Coverage

Neither drug is inexpensive without insurance. Addyi's list price has ranged from approximately $800 to $1,200 per month; Vyleesi's list price is roughly $950 to $1,100 for a four-dose kit. Both manufacturers offer patient assistance programs. Insurance coverage remains inconsistent, with many payers classifying HSDD medications as lifestyle drugs outside standard formulary coverage. Patients should verify coverage before prescribing to avoid unexpected out-of-pocket costs that lead to early discontinuation.

The Endocrine Society's clinical practice guidelines on female hypoactive sexual desire disorder note that cost and access barriers represent a meaningful factor in adherence to both approved therapies. Endocrine Society guidelines